Modulating the immune response with liposomal delivery

David Nardo; David Henson; Joe E. Springer; Vincent J. Venditto

doi:10.1016/B978-0-12-816705-2.00006-0

Modulating the immune response with liposomal delivery

David Nardo, David Henson, Joe E. Springer, Vincent J. Venditto

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

5 Scopus citations

Abstract

Lipid-based nanoparticles (LNPs) provide a platform for drug, gene, and vaccine delivery with clinical applicability to treat a variety of diseases. As advances in drug development and immune mechanisms of disease continue to evolve, LNPs are positioned to have a profound impact on the future of immunomodulatory therapeutics. This chapter offers an overview of the principles of liposomal therapeutics, and the immune system while highlighting the clinically relevant liposomal therapeutics focused on small-molecule drugs, genes, and vaccines. Using the current state of the field of liposomal therapeutics, and the lessons learned from these preclinical and clinical studies, we will be able to pave the way for future advances in clinical liposomal immunomodulation.

Original language	English
Title of host publication	Nanomaterials for Clinical Applications
Subtitle of host publication	Case Studies in Nanomedicines
Pages	159-211
Number of pages	53
ISBN (Electronic)	9780128167052
DOIs	https://doi.org/10.1016/B978-0-12-816705-2.00006-0
State	Published - Jan 1 2020

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Inc. All rights reserved.

Keywords

Drug delivery
gene delivery
immune modulation
liposome
vaccine

ASJC Scopus subject areas

General Engineering
General Materials Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-816705-2.00006-0

Cite this

@inbook{c0ffa5ddf82a4b5487fca2891363947c,

title = "Modulating the immune response with liposomal delivery",

abstract = "Lipid-based nanoparticles (LNPs) provide a platform for drug, gene, and vaccine delivery with clinical applicability to treat a variety of diseases. As advances in drug development and immune mechanisms of disease continue to evolve, LNPs are positioned to have a profound impact on the future of immunomodulatory therapeutics. This chapter offers an overview of the principles of liposomal therapeutics, and the immune system while highlighting the clinically relevant liposomal therapeutics focused on small-molecule drugs, genes, and vaccines. Using the current state of the field of liposomal therapeutics, and the lessons learned from these preclinical and clinical studies, we will be able to pave the way for future advances in clinical liposomal immunomodulation.",

keywords = "Drug delivery, gene delivery, immune modulation, liposome, vaccine",

author = "David Nardo and David Henson and Springer, {Joe E.} and Venditto, {Vincent J.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-816705-2.00006-0",

language = "English",

isbn = "9780128168769",

pages = "159--211",

booktitle = "Nanomaterials for Clinical Applications",

}

TY - CHAP

T1 - Modulating the immune response with liposomal delivery

AU - Nardo, David

AU - Henson, David

AU - Springer, Joe E.

AU - Venditto, Vincent J.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Lipid-based nanoparticles (LNPs) provide a platform for drug, gene, and vaccine delivery with clinical applicability to treat a variety of diseases. As advances in drug development and immune mechanisms of disease continue to evolve, LNPs are positioned to have a profound impact on the future of immunomodulatory therapeutics. This chapter offers an overview of the principles of liposomal therapeutics, and the immune system while highlighting the clinically relevant liposomal therapeutics focused on small-molecule drugs, genes, and vaccines. Using the current state of the field of liposomal therapeutics, and the lessons learned from these preclinical and clinical studies, we will be able to pave the way for future advances in clinical liposomal immunomodulation.

AB - Lipid-based nanoparticles (LNPs) provide a platform for drug, gene, and vaccine delivery with clinical applicability to treat a variety of diseases. As advances in drug development and immune mechanisms of disease continue to evolve, LNPs are positioned to have a profound impact on the future of immunomodulatory therapeutics. This chapter offers an overview of the principles of liposomal therapeutics, and the immune system while highlighting the clinically relevant liposomal therapeutics focused on small-molecule drugs, genes, and vaccines. Using the current state of the field of liposomal therapeutics, and the lessons learned from these preclinical and clinical studies, we will be able to pave the way for future advances in clinical liposomal immunomodulation.

KW - Drug delivery

KW - gene delivery

KW - immune modulation

KW - liposome

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85101503367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101503367&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-816705-2.00006-0

DO - 10.1016/B978-0-12-816705-2.00006-0

M3 - Chapter

AN - SCOPUS:85101503367

SN - 9780128168769

SP - 159

EP - 211

BT - Nanomaterials for Clinical Applications

ER -

Modulating the immune response with liposomal delivery

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this